Monitor for updates on the FDA Type A meeting and resubmission timeline. The stock is likely to face continued pressure until clarity on the path to approval is provided. Assess upcoming cash position and potential need for dilutive financing.
Price Chart
Executive Summary
Grace Therapeutics received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for GTx-104 in aneurysmal subarachnoid hemorrhage (aSAH). The FDA cited issues in Chemistry, Manufacturing, and Controls (CMC) and non-clinical data but did not request additional clinical trials. The company plans to resubmit the NDA after addressing the cited deficiencies.
Key Facts
- FDA issued a Complete Response Letter (CRL) for GTx-104 NDA due to CMC and non-clinical deficiencies
- Issues include leachables data, toxicology risk assessments, and manufacturing deficiencies at a contract manufacturer
- FDA did not request additional clinical data, and the STRIVE-ON trial met its primary endpoint
- Company intends to request a Type A meeting with the FDA and resubmit the NDA
- GTx-104 is a novel IV formulation of nimodipine targeting aSAH, a rare and life-threatening condition
Financial Impact
High risk to near-term revenue potential; GTx-104 was the lead asset with no approved products. Delay increases cash burn and financing risk for this $58M market cap company.
Risk Factors
- Regulatory delay or rejection of resubmission
- Increased cash burn without near-term revenue
- Potential need for additional clinical or manufacturing investments
- Competitive risk if development timeline extends significantly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-016324 |
| Document: ef20070593_ex99-1.htm | 0001140361-26-016324 |
| Document: 0001140361-26-016324-index-headers.html | 0001140361-26-016324 |
| Document: 0001140361-26-016324-index.html | 0001140361-26-016324 |
| Document: 0001140361-26-016324.txt | 0001140361-26-016324 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers